Kirsten Timms

Company: Myriad

Job title: Senior Vice President - Biomarker Discovery

Seminars:

Testing for Homologous Recombination Deficiency in Ovarian & Other Tumor Types 3:15 pm

Myriad developed the MyChoice CDx test to identify patients with homologous recombination deficient (HRD) tumors Many other HRD tests show limited agreement with the clinically validated companion diagnostic test MyChoice CDx is approved for ovarian cancer, but may have applications in breast and prostate cancerRead more

day: Day One Track B PM